Heart drug may unlock secrets of blood flow in sepsis
NCT ID NCT07657754
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how esmolol, a drug that slows the heart rate, affects the smallest blood vessels in people with septic shock—a severe infection that can lead to organ failure. Researchers will measure changes in blood flow under the tongue and other key pressures in the circulatory system. The goal is to understand these effects better, not to prove a treatment works. About 20 adults with septic shock and a fast heart rate will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
esmolol
What this could lead to
If successful, this could guide future treatments to improve blood flow in septic shock patients.
What could go wrong
This is a very small pilot study with only 20 patients, so results may not apply broadly. Esmolol can cause low blood pressure or slow heart rate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhu, 233000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College)
Wuhu, Anhui, 241000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••